BioVie (NASDAQ: BIVI): Poised for Significant Catalysts in 2023
9 months ago
BioVie is poised for significant catalysts in 2023, including data read out from its
Alzheimer’s Phase 3 trial, expected in Q3 2023, as well as interim data read outs
from the Company’s planned Phase 3 study in Parkinson’s. BioVie has multiple other efforts underway that may create additional catalysts and will be announced publicly when the Company deems appropriate. Learn more at: https://www.redchip.com/stocks/bivi
0:00 - Start
0:29 - Company Overview
3:35 - Market Potential
5:07 - Additional Late-stage Programs
7:15 - Upcoming Catalysts
8:00 - Management Team
9:27 - Value Proposition
Loading comments...
-
2:34
RedChip
9 months agoBioVie: Potential Blockbuster Late-Stage Programs Targeting Alzheimer’s & Parkinson’s
-
0:21
RedChip
9 months agoBioVie: Developing Breakthrough Therapies for Unmet Medical Needs
4 -
2:19
RaisingAwareness
1 year agoPrions Disease; We Have Papers to Prove That HIV (Glycoprotein 120) Was Inserted Into Spike Protein
7001 -
1:49:28
SVHI
2 months agoReversing + Preventing Cognitive Decline in Alzheimer’s Disease - Dale Bredesen (Nov 2020)
26 -
11:21
gmketfsystems
3 months agoAI in Biotech: 2 Top Picks to Invest In & 1 Company to Steer Clear Of
15 -
7:47
LeapIntoFoil
10 months agoNeuralink Gets FDA Approval For Human Trials, Unrelated Neuralinks Stock Rises
18 -
4:13
The Igonrant Entrepreneur
10 months agoThe First AI-Generated Drug Enters Human Trials, Pioneering a New Era in Medicine!
22 -
3:37
TrialSiteNews
1 year agoProvention Bio Announces $125 Million Term Loan Facility with Hercules Capital
45 -
3:57
Real Truth Real News
4 months ago🚨 BS Alert!! "Bought and Paid For" Scientists Are Now Warning That the Latest COVID Variant Could Trigger a “Heart Failure Pandemic” 🤣
8.4K49 -
1:38
RaisingAwareness
1 year agoDr. Ryan Cole: The Entire Lipid Nanoparticle Platform Needs to End
139